[Form 4] Iridex Corp Insider Trading Activity

Rhea-AI Filing Summary

Iridex Corp (IRIX) insider filing shows Chief Financial Officer Romeo R. Dizon, via attorney-in-fact, purchased 625 shares of common stock on 09/03/2025 at $1.36 per share, bringing his beneficial ownership to 53,625 shares.

Positive

• Insider purchase: CFO acquired 625 shares at $1.36, increasing reported beneficial ownership to 53,625 shares

Negative

• None.

Insights

Financial Analyst

TL;DR: Insider purchase of 625 shares at $1.36; small transaction with limited material impact.

The Form 4 documents a small open-market purchase by the company's CFO. The size of the purchase relative to total reported holdings is modest, increasing beneficial ownership to 53,625 shares. This type of disclosure is routine and does not indicate a change in corporate strategy or material financial condition. Investors typically view modest insider buys as a neutral-to-slightly-positive signal, but the transaction size limits its market significance.

Corporate Governance Expert

TL;DR: Properly executed Form 4 filing; no governance red flags evident from the disclosure.

The filing is complete and signed by an attorney-in-fact, documenting the CFO's purchase and updated beneficial ownership. There are no indications of amendments, derivative transactions, planned trading programs, or related-party issues in the submitted content. From a governance perspective, the disclosure meets reporting requirements and raises no immediate compliance concerns.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dizon Romeo R

(Last) (First) (Middle)

1212 TERRA BELLA AVENUE

(Street)

MOUNTAIN VIEW CA 94043

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
IRIDEX CORP [ IRIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/03/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/03/2025		P		625	A	$1.36	53,625	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Nilo De Castro, Attorney-in-fact for Romeo R. Dizon	09/04/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did the Form 4 for IRIX disclose?

The Form 4 reports that CFO Romeo R. Dizon purchased 625 shares on 09/03/2025 at $1.36 per share, bringing his ownership to 53,625 shares.

Who filed the Form 4 for IRIDEX (IRIX)?

The filing lists Romeo R. Dizon, Chief Financial Officer, and is signed by an attorney-in-fact, Nilo De Castro, on 09/04/2025.

Was the transaction in IRIX a purchase or sale?

The transaction code is P, indicating a purchase of 625 shares at $1.36 per share.

How much did the insider pay in total for the IRIX shares?

At $1.36 per share for 625 shares, the reported purchase amount totals $850.00 (transaction value as reported).

Does the Form 4 show any derivative transactions or trading plans?

No. Table II (derivative securities) contains no reported transactions and there is no indication of a Rule 10b5-1 trading plan in the provided content.